[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367378-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-367378-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","cervical-cancer-screening-a-comparative-study-of-truscreen-vs-pap-smear","Cervical cancer screening: a comparative study of TruScreen vs. Pap Smear","","This prospective observational pilot study evaluated TruScreen™ (TS), a real-time optoelectronic device, as an alternative or adjunct to Pap Smear using Liquid Based Cytology (LBC) for cervical cancer screening. A total of 507 women underwent TS and LBC after enrollment; abnormal findings proceeded to colposcopy and cervical biopsy within one month. TS showed 83.3% sensitivity and 95% specificity versus Pap smear 66.7% sensitivity and 98.2% specificity, with no statistically significant difference (p=0.91). TS also demonstrated notably high performance for CIN2+ lesions.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cervical-cancer-screening-a-comparative-study-of-truscreen-vs-pap-smear/367378/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cervical-cancer-screening-a-comparative-study-of-truscreen-vs-pap-smear/367378.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this study?","Question",{"text":63,"@type":64},"The study evaluated whether TruScreen™ could serve as an alternative or adjunct to Pap Smear (LBC) for cervical cancer screening.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and who participated?",{"text":68,"@type":64},"A prospective observational pilot study included 507 women followed at gynecology clinics. All participants received both TS and LBC, and abnormal results were referred for colposcopy and biopsy within one month.",{"name":70,"@type":61,"acceptedAnswer":71},"How did TruScreen compare with Pap smear in diagnostic performance?",{"text":72,"@type":64},"TruScreen showed 83.3% sensitivity and 95% specificity, while Pap smear showed 66.7% sensitivity and 98.2% specificity. The difference between screening tools was not statistically significant (p=0.91).",{"name":74,"@type":61,"acceptedAnswer":75},"What does the conclusion indicate about TruScreen’s clinical use?",{"text":76,"@type":64},"TruScreen demonstrated potential as a screening tool in this preliminary study and did not require cervical samples, laboratory equipment, or highly trained personnel, though larger studies are needed to confirm reliability and practicality.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},367378,1790745928,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Alhudhud etal. BMC Women’s Health (2025) 25:198 [https://doi.org/10.1186/s12905-025-03733-z](https://doi.org/10.1186/s12905-025-03733-z)  \nBMC Women’s Health  \n RESEARCH Open Access  \nCervical cancer screening: a comparative study of TruScreen vs. Pap Smear  \nMajed Alhudhud1* , Shazia Maqsood 1, Maab El Hussein 1, Rifat Shaheen1, Hiba Sarhan2, Sadia Aslam2, Hisham Al Khalidi3, Amina Butt4 and Mazen Bishtawi5  \nAbstract  \nObjectives This study aimed to evaluate the potential of real-time optoelectronic device (TruScreen™; TS; TruScreen Group Limited, New Zealand) as an alternative or adjunct to Pap Smear (Liquid Based Cytology (LBC)) for cervical cancer screening.  \nMethod We conducted a prospective observational pilot study involving 507 women who were routinely followed at gynecology clinics. All participants underwent TS and LBC examinations after study enrolment. Those with abnormal findings were referred for colposcopy and cervical biopsy within one month.  \nResults Overall, 507 women fulfilled the eligibility criteria and were included in this study, of which 30 women (5 . 9%) had abnormal TS findings and underwent colposcopy. Thirteen women (43 . 3%) had low-grade lesions, and only one (3 . 3%) had a high-grade lesion. Regarding biopsy findings, three women had cervical intraepithelial neoplasia (CIN) 1, two women had‘CIN2 +, and one had glandular hyperplasia. The TS yielded a sensitivity of 83 . 3%(95% CI: 35 .9–99. 6%) and a specificity of 95%(95% CI: 92 .7-96. 8%) for the detection of cervical abnormality, compared to 66 . 7%(95% CI: 22.3–95. 7%) and 98 . 2%(95%: CI 96 . 6%-99 . 2%) of the Pap smear, respectively. The difference between both screening tools was not statistically significant (p = 0 . 91) . The sensitivity (100%, 95% CI 15. 6–100%) and specificity (95 . 6%, 95% CI 93.4–97. 2%) ofTS and Pap smear for‘CIN2 + lesions were notably high.  \nConclusion TS demonstrated potential as a screening tool for cervical neoplasms in this preliminary study. The tool did not require cervical samples, laboratory equipment, or highly trained personnel. While our findings suggest the potential for real-time and accurate screening, further research with a larger sample size is necessary to confirm its reliability and practicality.  \nKeywords Cervical cancer, Optoelectronic cervical screening, TruScreen, Real-time screening, Optoelectronic device, Pap smear, CIN  \n*Correspondence: Majed Alhudhud[drhudhud@gmail.com](drhudhud@gmail.com)  \n1 Department of Obstetrics and Gynecology, Dr Sulaiman Alhabib Medical Group, Arrayan Hospital, P. O. Box: 100266 Riyadh, Khurais Road, Riyadh 11635, Saudi Arabia  \n2 Department of Obstetrics and Gynecology, Dr Sulaiman Alhabib Medical Group, Olaya Hospital, Riyadh, Saudi Arabia  \n3 Department of Histopathology, Dr SulaimanAlhabib Medical GroupProfessor Department of Pathology, College of Medicine, Medical Diagnostic Labs, King Saud University, Riyadh, Saudi Arabia  \n4 Department of Obstetrics and Gynecology, Dr Sulaiman Alhabib Medical Group, Takhassusi Hospital, Riyadh, Saudi Arabia  \n5 Department of Obstetrics and Gynecology, College of Medicine Qatar University, The View Hospital, Doha, Qatar  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended u","cbCaivzUW5aA6TDd","https://ap.wps.com/l/cbCaivzUW5aA6TDd","pdf",1334659,11,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"The study evaluated whether TruScreen™ could serve as an alternative or adjunct to Pap Smear (LBC) for cervical cancer screening.\"},{\"question\":\"How was the study conducted and who participated?\",\"answer\":\"A prospective observational pilot study included 507 women followed at gynecology clinics. All participants received both TS and LBC, and abnormal results were referred for colposcopy and biopsy within one month.\"},{\"question\":\"How did TruScreen compare with Pap smear in diagnostic performance?\",\"answer\":\"TruScreen showed 83.3% sensitivity and 95% specificity, while Pap smear showed 66.7% sensitivity and 98.2% specificity. The difference between screening tools was not statistically significant (p=0.91).\"},{\"question\":\"What does the conclusion indicate about TruScreen’s clinical use?\",\"answer\":\"TruScreen demonstrated potential as a screening tool in this preliminary study and did not require cervical samples, laboratory equipment, or highly trained personnel, though larger studies are needed to confirm reliability and practicality.\"}]","Cervical cancer screening: a comparative study of TruScreen vs. Pap Smear | PDF",1790170533,28,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f31c3ed9c915df1e8e4d73aaf791e6aa.webp",983,1305,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ec6df56326539bd0c9b893581ed8195.webp",982,1304,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/839b1310175764d9da1c5efdbbcf0d43.webp",981,1303,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4f3237bc4bf0aa383590a78cfd721b9.webp",980,1301]